11) HFV
Abstract
Hemorrhagic Fever Virus (HFV) - Broad-spectrum or platform-based MCM candidates will be advanced against viruses such as Ebola and Marburg through the Technology Development phase. Preclinical evaluation achieving IND status will be completed and will complete Phase I clinical studies where drug candidates are introduced into humans and early evidence is gathered on drug safety. TMT will conclude the TD Phase by completing all activities associated with Phase I clinical studies. The results of the TD Phase clinical studies will support a Milestone B decision to continue toward a New Drug Application (NDA) and FDA approval/licensure.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2013
- Source ID
- a35efe767863c11445356875560cedd9